• HTC Extraction (HTC) has completed its purchase of Kase Farma
  • Kase Farma is a cannabinoid manufacture licenced in California, U.S.
  • The Purchase was made for C$1.2 Million
  • Kase Farma is currently upgrading production at its California facility
  • HTC Extraction (HTC) was steady, with shares currently trading at C$0.20

LNG gas manufacturer, HTC Extraction ( HTC), has completed its purchase of American cannabinoid manufacturer Kase Farma Inc.

In a share and purchase agreement with Startling Brands Inc., the company acquired all the shares of Kase Farma, which is now a wholly owned subsidiary of HTC Extractions. 

The purchase consisted of a C$1,200,000 cash buy-out as well as large issuance of shares and warrants by HTC Extractions.  

Mike Reynolds, Starling Brands’ CEO stated he’s excited to work alongside HTC.

Kase Farma is authorised in California, U.S. and cultivates and extracts various hemp and CBD products.

The farm has an “Identity Preserved Initiative” which allows consumers to track where exactly the products have originated from.  

Kase Farma is currently upgrading its California plant. It hopes to bring production up to 435,000 grams each day. Running at this capacity, the gross revenue potential would be C$1.85 million a day.

Kase Farma’s is valuable to HTC for two reasons.

Firstly, as a producer of cannabinoids and secondly as a source of plant-based biomass for HTC Extractions’ renewable natural gas projects.

HTC Extraction (HTC) was steady, with shares currently trading at C$0.20

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.